Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mauro Angiolini is active.

Publication


Featured researches published by Mauro Angiolini.


Bioorganic & Medicinal Chemistry Letters | 2011

Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors

Marina Caldarelli; Mauro Angiolini; Teresa Disingrini; Daniele Donati; Marco Guanci; Stefano Nuvoloni; Helena Posteri; Francesca Quartieri; Marco Silvagni; Riccardo Colombo

The synthesis and SAR of a series of novel pyrazolo-quinazolines as potent and selective MPS1 inhibitors are reported. We describe the optimization of the initial hit, identified by screening the internal library collection, into an orally available, potent and selective MPS1 inhibitor.


European Journal of Organic Chemistry | 2000

Synthesis of Azabicycloalkane Amino Acid Scaffolds as Reverse-Turn Inducer Dipeptide Mimics

Mauro Angiolini; Silvia Araneo; Laura Belvisi; Edoardo Cesarotti; Anna Checchia; Luca Crippa; Leonardo Manzoni; Carlo Scolastico

In an effort to design dipeptide structural mimics of protein and peptide reverse-turns, a series of 5,5-, 6,5-, and 7,5-fused 2-oxo-1-azabicycloalkane amino acids has been synthesized. A new and convenient synthetic route utilizing a Horner−Emmons reaction followed by double-bond reduction has been used to prepare the bicyclic lactams in high yields.


Bioorganic & Medicinal Chemistry Letters | 2010

Structure-Based Optimization of Potent Pdk1 Inhibitors.

Mauro Angiolini; Patrizia Banfi; Elena Casale; Francesco Casuscelli; Claudio Fiorelli; Maria B. Saccardo; Marco Silvagni; Fabio Zuccotto

In this Letter is described the structure-based design of potent dihydro-pyrazoloquinazolines as PDK1 inhibitors. Starting from low potency HTS hits with the aid of X-ray crystallography and modeling, a medicinal chemistry activity was carried out to improve potency versus PDK1 and selectivity versus CDK2 protein kinase.


Bioorganic & Medicinal Chemistry Letters | 1997

Design and synthesis of conformationally constrained arginal thrombin inhibitors

Aldo Salimbeni; Fabio Paleari; Renato Canevotti; Marco Criscuoli; Annalisa Lippi; Mauro Angiolini; Laura Belvisi; Carlo Scolastico; Lino Colombo

A series of conformationally constrained arginal thrombin inhibitors was prepared starting from 5,6 or 5,7 bicyclic lactamic structures, that an indirect approach of X-ray structure-based drug design indicated as D-Phe-Pro dipeptide mimetics. The tetrahydroquinolyl sulfonamido derivative Ig (LR-D/009) displayed the best inhibitory potency (IC50 = 0.018 μm), with good selectivity over plasmin and trypsin.


Tetrahedron | 1998

Stereoselective synthesis of 6,5-bicyclic reverse-turn peptidomimetics

Lino Colombo; Marcello Di Giacomo; Gloria Brusotti; Nicola Sardone; Mauro Angiolini; Laura Belvisi; Sonia Maffioli; Leonardo Manzoni; Carlo Scolastico

Abstract A flexible stereoselective synthetic scheme was developed to prepare 6,5-fused bicyclic lactams, that molecular mechanics calculations revealed to have a potential as reverse-turn mimetics. The convergence of the synthetic sequence was achieved by attachment of a properly substituted malonate unit to the (2S)-cis-5-(2-hydroxyethyl)proline tert-butyl ester. Stereoselective intramolecular alkylation of the malonate afforded the 6-membered lactam fused to the 2-carbalkoxy pyrrolidine nucleus. X-ray diffraction analysis of a more advanced synthetic derivative allowed the unequivocal assignment of the configuration at the newly created quaternary stereocenter as R.


Bioorganic & Medicinal Chemistry | 1998

Design and synthesis of nonpeptide angiotensin II receptor antagonists featuring acyclic imidazole-mimicking structural units

Mauro Angiolini; Laura Belvisi; Davide Poma; Aldo Salimbeni; Nunzio Sciammetta; Carlo Scolastico

Extensive molecular modelling studies, including conformational analysis and the comparison of molecular electrostatic potential distributions, wee used to evaluate structural parameters of new antagonists containing acyclic replacements of the N = C-N imidazole region. The synthesis and the biological screening of a series of acyl biphenyltetrazole derivatives were planned and realized to gain an insight into the structure-activity relationships of this unusual class of Angiotensin II antagonists.


Journal of Medicinal Chemistry | 2010

Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation

Fabio Zuccotto; Elena Ardini; Elena Casale; Mauro Angiolini


Archive | 2012

Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Marina Caldarelli; Mauro Angiolini; Italo Beria; Maria Gabriella Brasca; Francesco Casuscelli; Roberto D'alessio; Andrea Lombardi Borgia


Archive | 2013

SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

Maria Menichincheri; Mauro Angiolini; Jay Aaron Bertrand; Michele Caruso; Paolo Polucci; Francesca Quartieri; Barbara Salom; Matteo Salsa; Fabio Zuccotto


Archive | 2014

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

Mauro Angiolini; Laura Buffa; Maria Menichincheri; Ilaria Motto; Paolo Polucci; Gabriella Traquandi; Fabio Zuccotto

Collaboration


Dive into the Mauro Angiolini's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maria Menichincheri

National University of Ireland

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge